{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:23:46Z","timestamp":1783661026189,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI176245"],"award-info":[{"award-number":["R01-AI176245"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100184","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:32:26Z","timestamp":1761089546000},"page":"100184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The anti-inflammatory drug celecoxib is metabolized by Pseudomonas aeruginosa CYP107S1 in vitro and in vivo"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-8035","authenticated-orcid":false,"given":"Sylvie E.","family":"Kandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-2263","authenticated-orcid":false,"given":"Jed N.","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2025.100184_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MBP-0002-2014","article-title":"Metabolic adaptations of intracellullar bacterial pathogens and their mammalian host cells during infection (\u201cpathometabolism\u201d)","volume":"3","author":"Eisenreich","year":"2015","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.dmd.2025.100184_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fcimb.2014.00029","article-title":"Shifting the paradigm from pathogens to pathobiome: new concepts in the light of meta-omics","volume":"4","author":"Vayssier-Taussat","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100184_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert","year":"2018","journal-title":"AIMS Microbiol"},{"key":"10.1016\/j.dmd.2025.100184_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1025633","article-title":"The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic","volume":"10","author":"Shariati","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.dmd.2025.100184_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41570-023-00472-3","article-title":"The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics","volume":"7","author":"Singh","year":"2023","journal-title":"Nat Rev Chem"},{"issue":"4","key":"10.1016\/j.dmd.2025.100184_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuae019","article-title":"Mechanisms of host adaptation by bacterial pathogens","volume":"48","author":"Barber","year":"2024","journal-title":"FEMS Microbiol Rev"},{"issue":"6704","key":"10.1016\/j.dmd.2025.100184_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi0908","article-title":"Evolution and host-specific adaptation of Pseudomonas aeruginosa","volume":"385","author":"Weimann","year":"2024","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.dmd.2025.100184_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1039\/D1MD00200G","article-title":"\u03b2-lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates","volume":"12","author":"Mora-Ochomogo","year":"2021","journal-title":"RSC Med Chem"},{"issue":"13","key":"10.1016\/j.dmd.2025.100184_bib9","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/acs.chemrev.1c00138","article-title":"Metallo-\u03b2-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design","volume":"121","author":"Bahr","year":"2021","journal-title":"Chem Rev"},{"issue":"8","key":"10.1016\/j.dmd.2025.100184_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107594","article-title":"Drug metabolism of ciprofloxacin, ivacaftor, and raloxifene by Pseudomonas aeruginosa cytochrome P450 CYP107S1","volume":"300","author":"Kandel","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dmd.2025.100184_bib11","series-title":"StatPearls [Internet]","article-title":"Ciprofloxacin","author":"Thai","year":"2023"},{"issue":"5","key":"10.1016\/j.dmd.2025.100184_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.dmd.2025.100184_bib13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1513\/AnnalsATS.201908-596ED","article-title":"Does ivacaftor taken twice a day keep the Pseudomonas away?","volume":"16","author":"Gifford","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.dmd.2025.100184_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1566524019666191014112133","article-title":"Selective estrogen receptor modulators (SERMs): mechanistic insights against microbial infections","volume":"20","author":"Garg","year":"2020","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.dmd.2025.100184_bib15","series-title":"Liver Immunology: Principles and Practice","first-page":"179","article-title":"Immune responses to bacterial infections","author":"Rigopoulou","year":"2020"},{"key":"10.1016\/j.dmd.2025.100184_bib16","series-title":"Encyclopedia of Infection and Immunity","first-page":"791","article-title":"Anti-inflammatory therapy of infections","author":"Kuchar","year":"2022"},{"issue":"4","key":"10.1016\/j.dmd.2025.100184_bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/QCO.0000000000001024","article-title":"NSAIDs for early management of acute respiratory infections","volume":"37","author":"Bassetti","year":"2024","journal-title":"Curr Opin Infect Dis"},{"issue":"9","key":"10.1016\/j.dmd.2025.100184_bib18","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/infdis\/jit594","article-title":"Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis","volume":"209","author":"Hamilton","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.dmd.2025.100184_bib19","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ejim.2017.03.004","article-title":"Bacterial infections and NSAIDs exposure? Seek septic complications","volume":"41","author":"Le Turnier","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100184_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077365","article-title":"NSAID prescribing and adverse outcomes in common infections: a population-based cohort study","volume":"14","author":"Stuart","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.dmd.2025.100184_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1741-7015-8-30","article-title":"Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - results of a randomized controlled pilot trial","volume":"8","author":"Bleidorn","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.dmd.2025.100184_bib22","article-title":"Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial","volume":"351","author":"G\u00e1gyor","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.dmd.2025.100184_bib23","article-title":"Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial","volume":"359","author":"Kronenberg","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.dmd.2025.100184_bib24","first-page":"365","article-title":"Is a combination of antibiotics and non-steroidal anti-inflammatory drugs more beneficial than antibiotic monotherapy for the treatment of female acute uncomplicated cystitis? A randomized controlled pilot study","volume":"15","author":"Ko","year":"2018","journal-title":"Urol J"},{"issue":"5","key":"10.1016\/j.dmd.2025.100184_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002569","article-title":"Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women\u2014a double-blind, randomized non-inferiority trial","volume":"15","author":"Vik","year":"2018","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.dmd.2025.100184_bib26","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1128\/AAC.00048-09","article-title":"Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis","volume":"53","author":"Chiu","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2025.100184_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5455\/2319-2003.ijbcp20130807","article-title":"Experimental antibacterial activity of selective cyclooxygenase antagonist","volume":"2","author":"Al-kuraishy","year":"2017","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100184_bib28","doi-asserted-by":"crossref","first-page":"e01574","DOI":"10.1128\/AAC.01574-17","article-title":"Antimicrobial activity of ibuprofen against cystic fibrosis-associated Gram-negative pathogens","volume":"62","author":"Shah","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmd.2025.100184_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1557333","article-title":"Anti-inflammatory drugs as potential antimicrobial agents: a review","volume":"16","author":"Okpala","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100184_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116947","article-title":"Ibuprofen-mediated potential inhibition of biofilm development and quorum sensing in Pseudomonas aeruginosa","volume":"237","author":"Dai","year":"2019","journal-title":"Life Sci"},{"issue":"23","key":"10.1016\/j.dmd.2025.100184_bib31","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.3390\/ijms21239312","article-title":"A celecoxib derivative eradicates antibiotic-resistant Staphylococcus aureus and biofilms by targeting YidC2 translocase","volume":"21","author":"Tzeng","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100184_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.707629","article-title":"Antimicrobial activity of non-steroidal anti-inflammatory drugs on biofilm: current evidence and potential for drug repurposing","volume":"12","author":"Paes Leme","year":"2021","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100184_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/AAC.00735-10","article-title":"Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor","volume":"55","author":"Kalle","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"D1","key":"10.1016\/j.dmd.2025.100184_bib34","doi-asserted-by":"crossref","first-page":"D646","DOI":"10.1093\/nar\/gkv1227","article-title":"Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database","volume":"44","author":"Winsor","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.dmd.2025.100184_bib36","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/anie.201809981","article-title":"Azetidine-containing alkaloids produced by a quorum-sensing regulated nonribosomal peptide synthetase pathway in Pseudomonas aeruginosa","volume":"58","author":"Hong","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"issue":"13","key":"10.1016\/j.dmd.2025.100184_bib37","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1021\/acs.orglett.9b01383","article-title":"Discovery and biosynthesis of azabicyclene, a conserved nonribosomal peptide in Pseudomonas aeruginosa","volume":"21","author":"Patteson","year":"2019","journal-title":"Org Lett"},{"issue":"41","key":"10.1016\/j.dmd.2025.100184_bib38","doi-asserted-by":"crossref","first-page":"E2823","DOI":"10.1073\/pnas.1214128109","article-title":"Strain-dependent diversity in the Pseudomonas aeruginosa quorum-sensing regulon","volume":"109","author":"Chugani","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.dmd.2025.100184_bib39","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1021\/jacs.1c13653","article-title":"Azetidomonamide and diazetidomonapyridone metabolites control biofilm formation and pigment synthesis in Pseudomonas aeruginosa","volume":"144","author":"Ernst","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.dmd.2025.100184_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101629","article-title":"Pseudomonas aeruginosa cytochrome P450 CYP168A1 is a fatty acid hydroxylase that metabolizes arachidonic acid to the vasodilator 19-HETE","volume":"298","author":"Tooker","year":"2022","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.dmd.2025.100184_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4172\/2161-0444.1000495","article-title":"1-aminobenzotriazole: a mechanism-based cytochrome P450 inhibitor and probe of cytochrome P450 biology","volume":"8","author":"de Montellano","year":"2018","journal-title":"Med Chem (Los Angeles)"},{"key":"10.1016\/j.dmd.2025.100184_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.109950","article-title":"Structural determination and characterisation of the CYP105Q4 cytochrome P450 enzyme from Mycobacterium marinum","volume":"754","author":"Mohamed","year":"2024","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"10.1016\/j.dmd.2025.100184_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1099\/jmm.0.05132-0","article-title":"Expression stability of six housekeeping genes: a proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR","volume":"52","author":"Savli","year":"2003","journal-title":"J Med Microbiol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100184_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2013\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.dmd.2025.100184_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-3565(24)39255-9","article-title":"Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor","volume":"293","author":"Tang","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100184_bib46","doi-asserted-by":"crossref","first-page":"e00321","DOI":"10.1128\/mBio.00321-19","article-title":"Identification of the bacterial biosynthetic gene clusters of the oral microbiome illuminates the unexplored social language of bacteria during health and disease","volume":"10","author":"Aleti","year":"2019","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.dmd.2025.100184_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01344-23","article-title":"Biosynthetic gene cluster signature profiles of pathogenic Gram-negative bacteria isolated from Egyptian clinical settings","volume":"11","author":"Abdelsalam","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"10","key":"10.1016\/j.dmd.2025.100184_bib48","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.3390\/app13106045","article-title":"Impact of cytochrome P450 enzymes on the phase I metabolism of drugs","volume":"13","author":"Iacopetta","year":"2023","journal-title":"Appl Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100184_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/03602532.2015.1011658","article-title":"Regioselective hydroxylation of steroid hormones by human cytochromes P450","volume":"47","author":"Niwa","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100184_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/atm-20-4289","article-title":"The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis","volume":"2","author":"Chen","year":"2014","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/j.dmd.2025.100184_bib51","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0006-2952(99)00192-6","article-title":"Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes","volume":"58","author":"Nadin","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100184_bib52","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/mol.58.6.1341","article-title":"Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites","volume":"58","author":"Marill","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100184_bib53","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/pro.3698","article-title":"Methionine in proteins: the Cinderella of the proteinogenic amino acids","volume":"28","author":"Aledo","year":"2019","journal-title":"Protein Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100184_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.300.2.399","article-title":"Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate","volume":"300","author":"Li","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100184_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2020.213600","article-title":"Molecular probes for human cytochrome P450 enzymes: recent progress and future perspectives","volume":"427","author":"Wu","year":"2021","journal-title":"Coord Chem Rev"},{"issue":"9","key":"10.1016\/j.dmd.2025.100184_bib56","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3390\/microorganisms11092329","article-title":"The deciphering of growth-dependent strategies for quorum-sensing networks in Pseudomonas aeruginosa","volume":"11","author":"Ju\u0159\u00edkov\u00e1","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.dmd.2025.100184_bib57","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","article-title":"Repurposing celecoxib as a topical antimicrobial agent","volume":"6","author":"Thangamani","year":"2015","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100184_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/dmd.108.024075","article-title":"Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator?","volume":"37","author":"Linder","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:21:11Z","timestamp":1773861671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0090955625094930"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100184","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-inflammatory drug celecoxib is metabolized by Pseudomonas aeruginosa CYP107S1 in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100184"}}